Dr. Klickstein currently serves as the CEO of Koslapp Therapeutics and brings a history of leadership from his time at Versanis Bio, which was acquired by Eli Lilly, and his tenure as Chief Innovation Officer at Adicet Bio. During his decade-long career at Novartis, he headed the New Indications Discovery Unit, focusing on the identification and evaluation of novel therapeutic targets. His career transition from a physician-scientist role at Harvard Medical School’s Brigham and Women’s Hospital to industry leadership provides a foundational expertise in translational research that Harbour BioMed aims to integrate into its current pipeline.
Harbour BioMed Adds Dr. Lloyd Klickstein to Immunology Advisory Board
With over twenty years of experience bridging clinical medicine and biopharma innovation, rheumatologist Dr. Lloyd Klickstein joins Harbour BioMed as Scientific Advisor for Immunology. His appointment arrives as the company seeks to leverage its proprietary antibody platforms to address critical gaps in the treatment of immunological diseases.
Dr. Jingsong Wang, CEO of Harbour BioMed, noted that Klickstein’s track record in advancing therapeutics from initial discovery through clinical development is vital for the company’s growth strategy. For his part, Klickstein emphasized the potential of the company’s antibody discovery engines, including the Harbour Mice platform, to provide new options for patients. The collaboration will focus on accelerating the development of next-generation antibody therapies and identifying new opportunities within the company’s existing immunology portfolio.
Comments (0)
No comments yet. Be the first!